Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Therapeutic Drug Monitoring: Overview and Classification01:16

Therapeutic Drug Monitoring: Overview and Classification

648
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
648
Cancer Survival Analysis01:21

Cancer Survival Analysis

870
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
870
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

1.4K
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
1.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Early Treatment Failure in Patients Receiving Ciltacabtagene-Autoleucel for Relapsed/Refractory Multiple Myeloma.

American journal of hematology·2026
Same author

Ixazomib, Cyclophosphamide, and Dexamethasone (ICd), With or Without Daratumumab in Relapsed Multiple Myeloma.

Clinical lymphoma, myeloma & leukemia·2026
Same author

Clinical Evaluation of Ex Vivo Expanded MUC1-Specific Peripheral Blood T Cells for Adoptive Immunotherapy in Relapsed/Refractory Multiple Myeloma.

Cancer research communications·2026
Same author

A multicenter study of progression risk and outcomes in solitary bone plasmacytoma with and without marrow involvement.

Blood advances·2026
Same author

EXaCT-2: an augmented and customizable oncology-focused whole exome sequencing platform.

NPJ precision oncology·2026
Same author

Real-World Description of Non-ICANS Neurologic Events Among Patients with Relapsed or Refractory Multiple Myeloma Treated with Ciltacabtagene Autoleucel Using Two Large US Databases.

Oncology and therapy·2026

Related Experiment Video

Updated: May 6, 2026

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.2K

Myeloma: classification and risk assessment.

Rafael Fonseca1, Jorge Monge

  • 1Division of Hematology and Oncology, Mayo Clinic in Arizona, Scottsdale, AZ..

Seminars in Oncology
|October 19, 2013
PubMed
Summary

Multiple myeloma (MM) is a complex cancer with diverse subtypes. Risk stratification into high-risk and not-high-risk MM guides personalized treatment and improves patient outcome discussions.

Area of Science:

  • Hematology
  • Oncology
  • Cancer Biology

Background:

  • Multiple myeloma (MM) is a heterogeneous plasma cell malignancy.
  • Recent advancements have significantly improved understanding of MM biology and treatment options.
  • Recognizing disease heterogeneity is crucial for effective patient management.

Purpose of the Study:

  • To highlight the importance of disease subtypes in multiple myeloma.
  • To emphasize the clinical utility of risk stratification in MM.
  • To inform prognosis and treatment planning based on risk assessment.

Main Methods:

  • Review of current understanding of multiple myeloma biology and classification.
  • Discussion of clinical approaches to risk stratification.
  • Analysis of the impact of risk stratification on patient outcomes and therapy.

More Related Videos

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
08:57

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors

Published on: May 17, 2024

3.1K
Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

9.9K

Related Experiment Videos

Last Updated: May 6, 2026

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.2K
Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
08:57

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors

Published on: May 17, 2024

3.1K
Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

9.9K

Main Results:

  • Multiple myeloma can be classified into multiple subtypes, each with distinct clinical and pathological features.
  • A practical clinical classification distinguishes between high-risk and not-high-risk MM.
  • Risk stratification tools are readily available and utilized in clinical practice.

Conclusions:

  • Understanding MM subtypes and risk stratification is essential for tailored therapy and accurate prognostic discussions.
  • Risk-stratified approaches significantly impact treatment planning and patient outcomes.
  • Continued research into genetic abnormalities promises further advancements in precision medicine for MM.